A phase II clinical trial of ganetespib (STA-9090) in previously treated patients with advanced esophagogastric cancers

被引：0
|
作者：
Kwak, Eunice Lee
Goyal, Lipika
Abrams, Thomas Adam
Carpenter, Amanda
Wolpin, Brian M.
Wadlow, Raymond Couric
Allen, Jill N.
Heist, Rebecca Suk
McCleary, Nadine Jackson
Chan, Jennifer A.
Goessling, Wolfram
Schrag, Deborah
Evans, Colleen
Ng, Kimmie
Enzinger, Peter C.
Ryan, David P.
机构：
[1] Massachusetts Gen Hosp Canc Ctr, Div Hematol & Oncol, Boston, MA USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA
[5] Virginia Canc Specialists, Fairfax, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4090
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial
    Robert S. Witte
    Judith Manola
    Patrick A. Burch
    Timothy Kuzel
    Eric L. Weinshel
    Patrick J. Loehrer
    Investigational New Drugs, 1998, 16 : 191 - 195
  • [32] Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial
    Witte, RS
    Manola, J
    Burch, PA
    Kuzel, T
    Weinshel, EL
    Loehrer, PJ
    INVESTIGATIONAL NEW DRUGS, 1998, 16 (02) : 191 - 195
  • [33] A Phase II trial of topotecan and gemcitabine in patients with previously treated, advanced nonsmall cell lung carcinoma
    Rinaldi, DA
    Lormand, NA
    Brierre, JE
    Cole, JL
    Barnes, BC
    Mills, G
    Yadlapati, S
    Fontenot, MF
    Buller, EJ
    Rainey, JM
    CANCER, 2002, 95 (06) : 1274 - 1278
  • [34] Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer
    Anderson, SE
    O'Reilly, EM
    Kelsen, DP
    Ilson, DH
    CANCER INVESTIGATION, 2003, 21 (04) : 512 - 516
  • [35] A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group
    Laurie, Scott A.
    Hao, Desiree
    Leighl, Natasha B.
    Goffin, John
    Khomani, Abderrahim
    Gupta, Ashish
    Addison, Christina L.
    Bane, Anita
    Seely, Jean
    Filion, Marc L.
    Pond, Gregory R.
    Levine, Mark N.
    LUNG CANCER, 2017, 104 : 65 - 69
  • [36] Phase II trial of single-agent ganetespib (STA-9090), a heat shock protein 90 (Hsp90) inhibitor in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel-based chemotherapy: Results of a Prostate Cancer Clinical Trials Consortium (PCCTC) study
    Heath, Elisabeth I.
    Stein, Mark N.
    Vaishampayan, Ulka N.
    Antonarakis, Emmanuel S.
    Liu, Glenn
    Sheng, Shijie
    Farrow, Katherine
    Smith, Daryn W.
    Heilbrun, Lance K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors.
    Goldman, J. W.
    Raju, R. N.
    Gordon, G. A.
    Vukovic, V. M.
    Bradley, R.
    Rosen, L. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] PHASE-II TRIAL OF CISPLATIN (CPDD) IN PREVIOUSLY TREATED PATIENTS WITH ADVANCED SOFT-TISSUE SARCOMA
    BRENNER, J
    MAGILL, GB
    SORDILLO, PP
    CHENG, EW
    YAGODA, A
    CANCER, 1982, 50 (10) : 2031 - 2033
  • [39] Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM).
    Wakelee, Heather A.
    Padda, Sukhmani Kaur
    Burns, Matthew
    Spittler, Aaron John
    Riess, Jonathan
    San Pedro-Salcedo, Melanie
    Ramchandran, Kavitha
    Gubens, Matthew A.
    Neal, Joel W.
    Loehrer, Patrick J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia
    Hocepied, AMLJ
    Falkson, CI
    Falkson, G
    SOUTH AFRICAN MEDICAL JOURNAL, 1996, 86 (05): : 549 - 550
12345